The selective targeting of CD44+ CRC cells has been successfully demonstrated by administering anti-KRAS siRNA that is loaded in poly hexamethylene biguanide (PHMB) and a chitosan complex coated with HA [170]. The gene discussed is CD44; the disease is colorectal carcinoma.